Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 11/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | VCP | P55072 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22093271 | 1.00 | MAT2A (0.48) | MAT2ATLR7CRHR1TRPM8ADORA2A | |
| SCHEMBL22103715 | 0.86 | MAT2A (0.51) | MAT2ATLR7ABCG2 | |
| SCHEMBL22103357 | 0.86 | MAT2A (0.51) | MAT2AADORA2AADORA1ABCG2 | |
| SCHEMBL22103390 | 0.85 | MAT2A (0.50) | MAT2ATLR7ABCG2 | |
| SCHEMBL29570761 | 0.85 | MAT2A (0.50) | MAT2ATLR7ABCG2 | |
| SCHEMBL22093252 | 0.85 | MAT2A (0.50) | MAT2ATLR7ABCG2 | |
| SCHEMBL22093507 | 0.85 | MAT2A (0.50) | MAT2AABCG2 | |
| SCHEMBL22093259 | 0.84 | MAT2A (0.55) | MAT2AABCG2 | |
| SCHEMBL29570999 | 0.84 | MAT2A (0.55) | MAT2AABCG2 | |
| SCHEMBL22093149 | 0.84 | MAT2A (0.49) | MAT2AABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| CN-119528824-A | 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-113166078-B | 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2024-11-19 | — | — | CN | disclosed |
| US-12115163-B2 | Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor | IDEAYA BIOSCIENCES, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240269143-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR | GLAXOSMITHKLINE LLC | 2024-08-15 | — | — | US | disclosed |
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20220106276-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | PRMT1, PRMT6, MAT2A | MAT2A 3/4885TLR7 4812/4885CRHR1 2000/4885 |
| US-20240269143-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR | PRMT1, PRMT6, MNAT1 | MAT2A 7/4885TLR7 4712/4885CRHR1 1021/4885 |
| US-20220106276-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | MAT2B, MAT2A, MAT1A | MAT2A 2/4885TLR7 4812/4885CRHR1 4112/4885 |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | MAT2A 2/4885TLR7 4812/4885CRHR1 4112/4885 |
| US-12115163-B2 | Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor | PRMT1, PRMT6, MAT2A | MAT2A 3/4885TLR7 4812/4885CRHR1 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.